Intercept Pharmaceuticals Stock Price, News & Analysis (NASDAQ:ICPT)

$61.62 0.01 (0.02 %)
(As of 12/15/2017 04:00 PM ET)
Previous Close$61.62
Today's Range$60.94 - $62.28
52-Week Range$54.98 - $135.59
Volume1.19 million shs
Average Volume574,536 shs
Market Capitalization$1.55 billion
P/E RatioN/A
Dividend YieldN/A
Beta-2.08

About Intercept Pharmaceuticals (NASDAQ:ICPT)

Intercept Pharmaceuticals logoIntercept Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company's product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions. The Company's product candidate, obeticholic acid (OCA), is a bile acid analog, a chemical substance that has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). In addition to OCA, it is developing other bile acid analog compounds targeting FXR and a second dedicated bile acid receptor called TGR5, which is a target of interest for the treatment of type 2 diabetes and other gastrointestinal indications. The Company is also developing other products INT-767 for the treatment of fibrosis and INT-777 for the treatment of type 2 diabetes.

Receive ICPT News and Ratings via Email

Sign-up to receive the latest news and ratings for ICPT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryBiotechnology
SectorHealthcare
SymbolNASDAQ:ICPT
CUSIP45845P10
Phone646-747-1000

Debt

Debt-to-Equity Ratio3.15%
Current Ratio5.95%
Quick Ratio5.95%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$24.95 million
Price / Sales61.99
Cash FlowN/A
Price / CashN/A
Book Value$12.69 per share
Price / Book4.86

Profitability

Trailing EPS($14.80)
Net Income$-412,830,000.00
Net Margins-175.64%
Return on Equity-206.99%
Return on Assets-49.52%

Miscellaneous

Employees456
Outstanding Shares25,100,000

Intercept Pharmaceuticals (NASDAQ:ICPT) Frequently Asked Questions

What is Intercept Pharmaceuticals' stock symbol?

Intercept Pharmaceuticals trades on the NASDAQ under the ticker symbol "ICPT."

How were Intercept Pharmaceuticals' earnings last quarter?

Intercept Pharmaceuticals Inc (NASDAQ:ICPT) announced its quarterly earnings data on Wednesday, November, 1st. The biopharmaceutical company reported ($2.89) earnings per share for the quarter, beating analysts' consensus estimates of ($3.48) by $0.59. The biopharmaceutical company earned $41.33 million during the quarter, compared to the consensus estimate of $36.95 million. Intercept Pharmaceuticals had a negative net margin of 175.64% and a negative return on equity of 206.99%. The company's revenue for the quarter was up 697.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($3.59) EPS. View Intercept Pharmaceuticals' Earnings History.

When will Intercept Pharmaceuticals make its next earnings announcement?

Intercept Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, February, 21st 2018. View Earnings Estimates for Intercept Pharmaceuticals.

Where is Intercept Pharmaceuticals' stock going? Where will Intercept Pharmaceuticals' stock price be in 2017?

21 brokerages have issued 1-year price objectives for Intercept Pharmaceuticals' stock. Their predictions range from $50.00 to $332.00. On average, they expect Intercept Pharmaceuticals' share price to reach $141.35 in the next year. View Analyst Ratings for Intercept Pharmaceuticals.

What are Wall Street analysts saying about Intercept Pharmaceuticals stock?

Here are some recent quotes from research analysts about Intercept Pharmaceuticals stock:

  • 1. Needham & Company LLC analysts commented, "Intercept reported $40.9M in WW 3Q17 Ocaliva sales, with $4.1M attributed to one-time accounting adjustment. Excluding adjustment, WW and U.S. Ocaliva sales were $36.8M and $32.5M, respectively, both in-line with our and consensus $36M and $33M ests. Company has completed safety review w/ independent committee and discussions w/ FDA are underway. Changes to U.S. label are expected by early 1Q18. Safety concerns appear to have had modest impact on NRX since FDA letter and we have reduced our ests accordingly. Long-term sales in PBC may be negatively impacted by large number of competing programs in development. Maintain HOLD." (11/1/2017)
  • 2. Cantor Fitzgerald analysts commented, "Emerging Safety Risks, but PBC Remains Intact. This morning, Intercept reported results demonstrating 3Q17 revenue growth to $36.8 million (excl. $4.1 million one-time increase in deferred revenue) from $31 million in 2Q17. While the FDA warning letter at the end of the quarter potentially shifts the risk-benefit profile of Ocaliva, an analysis of drug scripts provided by Intercept indicates that the sharp drop in scripts around the time of the news has since abated. Net ex-U.S 3Q17 sales increased to $4.7 million from $2.5 million in 2Q17 during the quarter, largely contributed from Germany and France. No formal guidance for the full-year was given, but management noted that they expect sequential quarterly growth for the balance of 2017. While we do not see a negative impact to our long-run commercialization in PBC, we believe the safety events reaffirm the uncertainty for Ocaliva’s use in NASH (where dosing is higher)." (11/1/2017)
  • 3. Wells Fargo & Company analysts commented, "an increased risk of serious liver injury and death." The letter resulted in a 25 percent selloff in Intercept's stock on Thursday, and some Wall Street analyst's felt it prudent to take action.Wells Fargo's Jim Birchenough downgraded Intercept's stock rating from Overweight to Market Perform with a price target slashed from $265 all the way down to $95 as the letter goes beyond a previous warning.The FDA's letter contains new pieces of information that weren't included in the prior "Dear Healthcare Provider Letter," the analyst highlighted. For example, 19 separate deaths have been identified since Ocaliva's launch in May 2016. The cause of death was worsening primary biliary cholangitis in seven of these cases, cardiovascular disease in one case, with the other cases being unknown.Among the eight cases with a known cause of death, seven of the patients received an incorrect dose, Birchenough continued. In addition, the FDA highlighted 11 cases of serious liver injury, of which six patients were given an incorrect dose resulting in three of the 19 deaths."We believe that serious events in patients with mild or no baseline liver disease, treated with correct doses of OCALIVA, and the recommendation for increased monitoring could dramatically impact OCALIVA adoption in PBC, and introduces a potential overhang on the development for non alcoholic steatohepatitis (NASH), with phase 3 data not expected until early 2019 and potential increased risk of imbalance in serious adverse events (SAE's)," (9/21/2017)
  • 4. According to Zacks Investment Research, "Intercept received a boost with the approval of Ocaliva in 2016 and the initial uptake of the same has been encouraging. The drug’s sale is expected to pick up further in 2017. The PBC market holds strong potential.  We are also encouraged by Intercept’s efforts to develop the drug for additional indications. A potential label expansion of the drug will further boost sales. The company does not expect much contribution from international markets in 2017 and most of it will be loaded in the second half as it works to obtain reimbursements in various European countries. However, expenses are expected to continue to rise as the company invests in commercial activities related to Ocaliva. We also remain concerned about the lack of other late-stage candidates in Intercept’s pipeline.  Moreover, the company’s share underperformed the industry in the last one year." (7/11/2017)
  • 5. Cowen Inc analysts commented, "We hosted a group investor lunch recently with ICPT management." (6/12/2017)

Who are some of Intercept Pharmaceuticals' key competitors?

Who are Intercept Pharmaceuticals' key executives?

Intercept Pharmaceuticals' management team includes the folowing people:

  • Paolo Fundaro, Independent Chairman of the Board
  • Mark Pruzanski M.D., President, Chief Executive Officer, Director
  • Sandip S. Kapadia, Chief Financial Officer, Treasurer
  • Lisa Bright, President, International
  • Jerome Benedict Durso, Chief Operating Officer
  • David A Ford, Chief Human Resource Officer
  • , Bio & Compensation - 
  • Richard Kim, Senior Vice President, Commercial U.S.
  • Rachel L. McMinn Ph.D., Chief Business and Strategy Officer
  • David M. Shapiro M.D., Chief Medical Officer
  • Srinivas Akkaraju M.D. Ph.D., Independent Director

Who owns Intercept Pharmaceuticals stock?

Intercept Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Senvest Management LLC (2.33%), Orbimed Advisors LLC (1.54%), First Trust Advisors LP (1.20%), Bank of New York Mellon Corp (0.31%), National Planning Corp (0.28%) and Point72 Asset Management L.P. (0.23%). Company insiders that own Intercept Pharmaceuticals stock include Barbara Gayle Duncan, Daniel G Welch, David Shapiro, Lisa Bright, Mark Pruzanski, Rachel Mcminn, Richard J Kim and Sandip Kapadia. View Institutional Ownership Trends for Intercept Pharmaceuticals.

Who sold Intercept Pharmaceuticals stock? Who is selling Intercept Pharmaceuticals stock?

Intercept Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, Macquarie Group Ltd., Point72 Asset Management L.P., Schwab Charles Investment Management Inc., Candriam Luxembourg S.C.A., Pictet Asset Management Ltd. and California State Teachers Retirement System. Company insiders that have sold Intercept Pharmaceuticals company stock in the last year include Daniel G Welch, David Shapiro, Lisa Bright, Mark Pruzanski, Rachel Mcminn, Richard J Kim and Sandip Kapadia. View Insider Buying and Selling for Intercept Pharmaceuticals.

Who bought Intercept Pharmaceuticals stock? Who is buying Intercept Pharmaceuticals stock?

Intercept Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Senvest Management LLC, Royce & Associates LP, Cowen Inc., National Planning Corp, Stonepine Capital Management LLC, Fisher Asset Management LLC, First Trust Advisors LP and GSA Capital Partners LLP. View Insider Buying and Selling for Intercept Pharmaceuticals.

How do I buy Intercept Pharmaceuticals stock?

Shares of Intercept Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Intercept Pharmaceuticals' stock price today?

One share of Intercept Pharmaceuticals stock can currently be purchased for approximately $61.62.

How big of a company is Intercept Pharmaceuticals?

Intercept Pharmaceuticals has a market capitalization of $1.55 billion and generates $24.95 million in revenue each year. The biopharmaceutical company earns $-412,830,000.00 in net income (profit) each year or ($14.80) on an earnings per share basis. Intercept Pharmaceuticals employs 456 workers across the globe.

How can I contact Intercept Pharmaceuticals?

Intercept Pharmaceuticals' mailing address is 10 Hudson Yards 37th FL, New York NY, 10001. The biopharmaceutical company can be reached via phone at 646-747-1000 or via email at [email protected]


MarketBeat Community Rating for Intercept Pharmaceuticals (ICPT)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  734 (Vote Outperform)
Underperform Votes:  363 (Vote Underperform)
Total Votes:  1,097
MarketBeat's community ratings are surveys of what our community members think about Intercept Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Intercept Pharmaceuticals (NASDAQ:ICPT) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.382.382.452.37
Ratings Breakdown: 2 Sell Rating(s)
9 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
9 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
3 Sell Rating(s)
5 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
3 Sell Rating(s)
6 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $151.29$156.29$198.70$185.63
Price Target Upside: 149.48% upside153.59% upside126.93% upside57.34% upside

Intercept Pharmaceuticals (NASDAQ:ICPT) Consensus Price Target History

Price Target History for Intercept Pharmaceuticals (NASDAQ:ICPT)

Intercept Pharmaceuticals (NASDAQ:ICPT) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/12/2017Deutsche BankInitiated CoverageBuy$106.00HighView Rating Details
11/28/2017Leerink SwannReiterated RatingHold$60.00LowView Rating Details
11/20/2017WedbushReiterated RatingBuy$253.00N/AView Rating Details
11/1/2017Needham & Company LLCReiterated RatingHoldN/AView Rating Details
11/1/2017CowenReiterated RatingBuy$112.00N/AView Rating Details
11/1/2017Cantor FitzgeraldUpgradeUnderweight -> Neutral$69.00N/AView Rating Details
11/1/2017LaidlawUpgradeHold -> Buy$90.00N/AView Rating Details
10/24/2017OppenheimerReiterated RatingHoldN/AView Rating Details
10/13/2017Bank of AmericaLower Price TargetUnderperform$102.00 -> $73.00N/AView Rating Details
10/6/2017Goldman Sachs GroupReiterated RatingNeutral -> Neutral$79.00N/AView Rating Details
10/6/2017Seaport Global SecuritiesReiterated RatingBuy$136.00N/AView Rating Details
10/4/2017Royal Bank of CanadaReiterated RatingOutperform -> OutperformHighView Rating Details
10/4/2017JMP SecuritiesDowngradeOutperform -> Market PerformHighView Rating Details
9/26/2017Credit Suisse GroupReiterated RatingOutperform$201.00LowView Rating Details
9/26/2017Jefferies GroupReiterated RatingBuy$275.00 -> $135.00LowView Rating Details
9/23/2017Robert W. BairdReiterated RatingOutperform$332.00LowView Rating Details
9/22/2017BMO Capital MarketsReiterated RatingOutperform$221.00 -> $160.00HighView Rating Details
9/22/2017Morgan StanleyReiterated RatingUnderweight$75.00 -> $50.00HighView Rating Details
9/22/2017CitigroupDowngradeBuy -> Neutral$150.00 -> $92.00HighView Rating Details
9/21/2017Wells Fargo & CompanyDowngradeOutperform -> Market Perform$265.00 -> $95.00HighView Rating Details
2/16/2017FBR & CoReiterated RatingMarket Perform$200.00N/AView Rating Details
6/1/2016BarclaysReiterated RatingBuy$200.00 -> $205.00N/AView Rating Details
1/28/2016S&P Equity ResearchReiterated RatingAverage$100.60 -> $111.91N/AView Rating Details
(Data available from 12/16/2015 forward)

Earnings

Intercept Pharmaceuticals (NASDAQ:ICPT) Earnings History and Estimates Chart

Earnings by Quarter for Intercept Pharmaceuticals (NASDAQ:ICPT)

Intercept Pharmaceuticals (NASDAQ ICPT) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/21/2018($3.39)N/AView Earnings Details
11/1/2017Q3 2017($3.48)($2.89)$36.95 million$41.33 millionViewN/AView Earnings Details
7/31/2017Q2 2017($3.62)($3.46)$27.50 million$30.89 millionViewN/AView Earnings Details
5/4/2017Q1 2017($4.27)($3.61)$15.88 million$21.00 millionViewListenView Earnings Details
2/23/2017Q416($3.74)($4.84)$8.96 million$13.00 millionViewN/AView Earnings Details
11/3/2016Q316($3.82)($3.59)$4.77 million$4.70 millionViewN/AView Earnings Details
8/4/2016Q216($3.69)($3.14)$1.72 million$5.52 millionViewN/AView Earnings Details
5/5/2016Q1($3.60)($3.33)$0.49 million$0.45 millionViewN/AView Earnings Details
2/23/2016Q415($3.15)($3.62)$0.43 million$0.45 millionViewListenView Earnings Details
11/9/2015Q315($2.74)($2.10)$0.42 million$0.45 millionViewN/AView Earnings Details
8/5/2015Q215($1.95)($1.99)$2.17 million$0.45 millionViewN/AView Earnings Details
5/11/2015Q115($1.75)($1.78)$1.70 million$1.70 millionViewListenView Earnings Details
3/2/2015Q414($1.53)($1.63)$0.42 million$0.04 millionViewN/AView Earnings Details
11/6/2014Q3($1.10)($1.69)$0.46 million$0.45 millionViewN/AView Earnings Details
8/11/2014Q214($1.10)$1.51$400.00 million$405.40 millionViewN/AView Earnings Details
5/7/2014Q1 2014($0.72)($1.59)$0.41 million$0.41 millionViewN/AView Earnings Details
3/14/2014Q4 13($0.70)($0.64)ViewN/AView Earnings Details
11/14/2013Q313($0.51)($1.65)$0.89 millionViewN/AView Earnings Details
8/13/2013Q2 2013($0.51)($0.79)$0.40 million$0.41 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Intercept Pharmaceuticals (NASDAQ:ICPT) Earnings Estimates

2017 EPS Consensus Estimate: ($14.72)
2018 EPS Consensus Estimate: ($13.79)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20174($4.62)($3.39)($4.02)
Q2 20175($3.87)($3.28)($3.66)
Q3 20175($3.78)($3.49)($3.61)
Q4 20176($4.29)($2.11)($3.42)
Q1 20183($3.71)($3.30)($3.53)
Q2 20183($4.12)($3.06)($3.45)
Q3 20183($4.63)($2.57)($3.43)
Q4 20183($5.23)($2.09)($3.39)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Intercept Pharmaceuticals (NASDAQ:ICPT)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Intercept Pharmaceuticals (NASDAQ ICPT) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 9.20%
Institutional Ownership Percentage: 73.80%
Insider Trades by Quarter for Intercept Pharmaceuticals (NASDAQ:ICPT)
Institutional Ownership by Quarter for Intercept Pharmaceuticals (NASDAQ:ICPT)

Intercept Pharmaceuticals (NASDAQ ICPT) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/2/2017David ShapiroCMOSell349$58.90$20,556.10View SEC Filing  
10/2/2017Mark PruzanskiCEOSell1,532$58.87$90,188.84View SEC Filing  
10/2/2017Rachel McminnInsiderSell283$58.89$16,665.87View SEC Filing  
10/2/2017Richard J KimSVPSell48$58.10$2,788.80View SEC Filing  
10/2/2017Sandip KapadiaCFOSell354$58.83$20,825.82View SEC Filing  
9/1/2017David ShapiroCMOSell1,250$117.43$146,787.50View SEC Filing  
8/25/2017Lisa BrightInsiderSell253$111.31$28,161.43View SEC Filing  
8/2/2017Lisa BrightInsiderSell142$110.29$15,661.18View SEC Filing  
8/1/2017David ShapiroCMOSell1,118$119.00$133,042.00View SEC Filing  
7/31/2017Daniel G WelchDirectorSell602$123.93$74,605.86View SEC Filing  
7/31/2017Rachel McminnInsiderSell130$123.12$16,005.60View SEC Filing  
7/20/2017Daniel G WelchDirectorSell217$126.76$27,506.92View SEC Filing  
7/14/2017Richard J KimSVPSell89$128.64$11,448.96View SEC Filing  
7/11/2017David ShapiroCMOSell553$124.01$68,577.53View SEC Filing  
7/3/2017David ShapiroCMOSell350$121.24$42,434.00View SEC Filing  
7/3/2017Lisa BrightInsiderSell394$121.33$47,804.02View SEC Filing  
7/3/2017Mark PruzanskiCEOSell1,434$121.78$174,632.52View SEC Filing  
7/3/2017Richard J KimSVPSell50$121.69$6,084.50View SEC Filing  
7/3/2017Sandip KapadiaCFOSell1,431$121.59$173,995.29View SEC Filing  
6/26/2017Mark PruzanskiCEOSell40,000$130.80$5,232,000.00View SEC Filing  
6/1/2017Lisa BrightInsiderSell698$110.73$77,289.54View SEC Filing  
5/25/2017Lisa BrightInsiderSell254$117.52$29,850.08View SEC Filing  
5/16/2017Lisa BrightInsiderSell113$119.74$13,530.62View SEC Filing  
5/2/2017Lisa BrightInsiderSell426$114.00$48,564.00View SEC Filing  
5/1/2017David ShapiroCMOSell1,117$112.18$125,305.06View SEC Filing  
5/1/2017Rachel McminnInsiderSell114$113.12$12,895.68View SEC Filing  
4/10/2017David ShapiroCMOSell558$108.51$60,548.58View SEC Filing  
4/3/2017David ShapiroCMOSell346$115.00$39,790.00View SEC Filing  
4/3/2017Lisa BrightInsiderSell389$115.00$44,735.00View SEC Filing  
4/3/2017Mark PruzanskiCEOSell1$115.00$115.00View SEC Filing  
2/27/2017Lisa BrightInsiderSell254$119.48$30,347.92View SEC Filing  
1/31/2017Lisa BrightInsiderSell134$108.96$14,600.64View SEC Filing  
1/9/2017David ShapiroCMOSell1,565$106.01$165,905.65View SEC Filing  
1/3/2017David ShapiroCMOSell988$103.92$102,672.96View SEC Filing  
1/3/2017Mark PruzanskiCEOSell2,802$103.92$291,183.84View SEC Filing  
1/3/2017Rachel McminnInsiderSell816$103.92$84,798.72View SEC Filing  
12/2/2016David ShapiroCMOSell1,350$99.75$134,662.50View SEC Filing  
11/25/2016Lisa BrightInsiderSell249$113.60$28,286.40View SEC Filing  
10/31/2016Rachel McminnInsiderSell129$123.82$15,972.78View SEC Filing  
10/10/2016David ShapiroCMOSell411$153.34$63,022.74View SEC Filing  
10/3/2016Barbara Gayle DuncanCAOSell147$163.20$23,990.40View SEC Filing  
10/3/2016David ShapiroCMOSell1,513$163.08$246,740.04View SEC Filing  
10/3/2016Lisa BrightInsiderSell155$163.20$25,296.00View SEC Filing  
10/3/2016Mark PruzanskiCEOSell705$163.20$115,056.00View SEC Filing  
9/26/2016David ShapiroCMOSell3,545$165.08$585,208.60View SEC Filing  
9/20/2016Mark PruzanskiCEOSell35,000$165.00$5,775,000.00View SEC Filing  
8/25/2016Lisa BrightInsiderSell246$159.00$39,114.00View SEC Filing  
8/1/2016Rachel McminnInsiderSell125$176.57$22,071.25View SEC Filing  
7/5/2016Barbara Gayle DuncanCAOSell146$145.11$21,186.06View SEC Filing  
7/5/2016David ShapiroCMOSell163$145.11$23,652.93View SEC Filing  
7/5/2016Lisa BrightInsiderSell155$145.11$22,492.05View SEC Filing  
7/5/2016Mark PruzanskiCEOSell714$145.11$103,608.54View SEC Filing  
5/25/2016Lisa BrightInsiderSell251$137.50$34,512.50View SEC Filing  
5/2/2016Rachel McminnInsiderSell130$147.49$19,173.70View SEC Filing  
4/4/2016Barbara Gayle DuncanCFOSell144$130.76$18,829.44View SEC Filing  
4/4/2016David ShapiroCMOSell165$130.76$21,575.40View SEC Filing  
4/4/2016Lisa BrightInsiderSell153$130.76$20,006.28View SEC Filing  
4/4/2016Mark PruzanskiCEOSell708$130.76$92,578.08View SEC Filing  
2/25/2016Lisa BrightInsiderSell241$115.22$27,768.02View SEC Filing  
2/1/2016Rachel McminnInsiderSell128$103.56$13,255.68View SEC Filing  
1/13/2016Lisa BrightinsiderSell728$125.52$91,378.56View SEC Filing  
1/4/2016Barbara Gayle DuncanCFOSell468$145.90$68,281.20View SEC Filing  
1/4/2016David ShapiroCMOSell533$145.90$77,764.70View SEC Filing  
1/4/2016Mark PruzanskiCEOSell2,126$145.90$310,183.40View SEC Filing  
1/4/2016Rachel McminnInsiderSell469$145.90$68,427.10View SEC Filing  
11/25/2015Lisa BrightInsiderSell1,150$182.96$210,404.00View SEC Filing  
11/16/2015David ShapiroCMOSell4,264$178.53$761,251.92View SEC Filing  
11/10/2015David ShapiroCMOSell3,500$204.15$714,525.00View SEC Filing  
11/10/2015Klaus R. Dr VeitingerDirectorSell1,000$198.25$198,250.00View SEC Filing  
11/2/2015Rachel McminnInsiderSell125$160.24$20,030.00View SEC Filing  
10/2/2015Barbara Gayle DuncanCFOSell1,054$163.17$171,981.18View SEC Filing  
10/2/2015David ShapiroCMOSell1,140$160.12$182,536.80View SEC Filing  
9/21/2015Nicole WilliamsDirectorSell973$194.82$189,559.86View SEC Filing  
9/15/2015David ShapiroCMOSell3,500$191.28$669,480.00View SEC Filing  
8/17/2015David ShapiroCMOSell4,272$209.37$894,428.64View SEC Filing  
7/20/2015Nicole WilliamsDirectorSell973$279.01$271,476.73View SEC Filing  
7/10/2015Mark PruzanskiCEOSell12,500$250.00$3,125,000.00View SEC Filing  
7/6/2015Luciano AdoriniInsiderSell4,067$579.93$2,358,575.31View SEC Filing  
7/1/2015Barbara Gayle DuncanCFOSell1,000$242.10$242,100.00View SEC Filing  
7/1/2015David ShapiroCMOSell3,781$238.66$902,373.46View SEC Filing  
6/22/2015Nicole WilliamsDirectorSell974$265.14$258,246.36View SEC Filing  
6/15/2015David ShapiroCMOSell3,500$241.58$845,530.00View SEC Filing  
6/8/2015Luciano AdoriniInsiderSell4,000$248.40$993,600.00View SEC Filing  
5/11/2015Klaus R Dr VeitingerDirectorSell391$279.07$109,116.37View SEC Filing  
5/6/2015Luciano AdoriniInsiderSell4,000$259.97$1,039,880.00View SEC Filing  
4/20/2015Nicole WilliamsDirectorSell974$278.50$271,259.00View SEC Filing  
4/6/2015Luciano AdoriniInsiderSell4,000$269.64$1,078,560.00View SEC Filing  
4/2/2015David ShapiroCMOSell3,459$275.25$952,089.75View SEC Filing  
3/26/2015Orbimed Advisors LlcDirectorSell157,200$286.75$45,077,100.00View SEC Filing  
3/25/2015Orbimed Advisors LlcDirectorSell207,800$274.41$57,022,398.00View SEC Filing  
3/24/2015Jonathan SilversteinDirectorSell45,600$272.00$12,403,200.00View SEC Filing  
3/23/2015Jonathan SilversteinDirectorSell159,400$275.18$43,863,692.00View SEC Filing  
3/16/2015David ShapiroCMOSell3,500$286.90$1,004,150.00View SEC Filing  
1/12/2015Klaus R Dr VeitingerDirectorSell233$150.01$34,952.33View SEC Filing  
1/5/2015Barbara Gayle DuncanCFOSell141$176.49$24,885.09View SEC Filing  
1/5/2015Daniel Paul ReganInsiderSell146$176.49$25,767.54View SEC Filing  
1/5/2015David ShapiroCMOSell664$172.63$114,626.32View SEC Filing  
1/5/2015Mark PruzanskiCEOSell461$176.49$81,361.89View SEC Filing  
1/2/2015Barbara Gayle DuncanCFOSell1,000$156.40$156,400.00View SEC Filing  
11/17/2014David ShapiroCMOSell4,790$158.82$760,747.80View SEC Filing  
11/12/2014Srinivas AkkarajuDirectorBuy2,000$167.19$334,380.00View SEC Filing  
11/10/2014Klaus R Dr VeitingerDirectorSell233$175.95$40,996.35View SEC Filing  
11/3/2014Mark PruzanskiCEOSell10,000$259.41$2,594,100.00View SEC Filing  
10/10/2014Klaus R Dr VeitingerDirectorSell391$223.65$87,447.15View SEC Filing  
10/2/2014David ShapiroCMOSell5,020$231.63$1,162,782.60View SEC Filing  
10/1/2014Barbara Gayle DuncanCFOSell1,000$233.12$233,120.00View SEC Filing  
10/1/2014David ShapiroCMOSell4,188$231.17$968,139.96View SEC Filing  
10/1/2014Mark PruzanskiCEOSell10,000$228.82$2,288,200.00View SEC Filing  
9/15/2014David ShapiroCMOSell4,000$281.19$1,124,760.00View SEC Filing  
9/10/2014Klaus R Dr VeitingerDirectorSell391$280.50$109,675.50View SEC Filing  
9/2/2014Mark PruzanskiCEOSell10,000$286.49$2,864,900.00View SEC Filing  
8/27/2014David ShapiroCMOSell10,000$293.93$2,939,300.00View SEC Filing  
8/26/2014Orbimed Advisors LlcDirectorSell111,258$298.06$33,161,559.48View SEC Filing  
8/25/2014Jonathan SilversteinDirectorSell50,000$295.59$14,779,500.00View SEC Filing  
8/15/2014David ShapiroCMOSell4,774$291.49$1,391,573.26View SEC Filing  
8/12/2014Daniel Paul ReganInsiderSell8,124$325.70$2,645,986.80View SEC Filing  
8/12/2014Klaus R Dr VeitingerDirectorSell316$345.62$109,215.92View SEC Filing  
8/1/2014Mark PruzanskiCEOSell10,000$226.72$2,267,200.00View SEC Filing  
7/10/2014Klaus R Dr VeitingerDirectorSell391$219.15$85,687.65View SEC Filing  
7/7/2014Lorenzo TallarigoDirectorSell2,000$243.06$486,120.00View SEC Filing  
7/2/2014David ShapiroCMOSell5,036$244.73$1,232,460.28View SEC Filing  
7/1/2014Mark PruzanskiCEOSell10,000$250.61$2,506,100.00View SEC Filing  
6/16/2014David ShapiroCMOSell4,000$278.15$1,112,600.00View SEC Filing  
6/2/2014Mark PruzanskiCEOSell10,000$230.60$2,306,000.00View SEC Filing  
5/9/2014Lorenzo TallarigoDirectorSell2,007$254.68$511,142.76View SEC Filing  
5/1/2014Mark PruzanskiCEOSell10,000$263.17$2,631,700.00View SEC Filing  
4/16/2014Mark PruzanskiCEOSell10,000$242.22$2,422,200.00View SEC Filing  
4/14/2014Barbara Gayle DuncanCFOSell1,154$279.00$321,966.00View SEC Filing  
4/10/2014Lorenzo TallarigoDirectorSell349,318$317.71$110,981,821.78View SEC Filing  
4/9/2014Orbimed Advisors LlcDirectorSell81,305$320.00$26,017,600.00View SEC Filing  
4/7/2014Luciano AdoriniInsiderSell2,000$283.90$567,800.00View SEC Filing  
4/2/2014David ShapiroCMOSell5,393$331.83$1,789,559.19View SEC Filing  
3/17/2014David ShapiroCMOSell4,456$437.49$1,949,455.44View SEC Filing  
2/14/2014Paolo FundaroDirectorSell7,246$375.26$2,719,133.96View SEC Filing  
1/16/2014Mark PruzanskiCEOSell10,000$273.68$2,736,800.00View SEC Filing  
1/16/2014Srinivas AkkarajuDirectorSell3,250$267.94$870,805.00View SEC Filing  
1/8/2014David ShapiroCMOSell4,928$71.85$354,076.80View SEC Filing  
1/7/2014Lorenzo TallarigoDirectorSell1,839$67.41$123,966.99View SEC Filing  
1/7/2014Luciano AdoriniInsiderSell1,634$67.41$110,147.94View SEC Filing  
12/16/2013David ShapiroCMOSell5,016$62.11$311,543.76View SEC Filing  
10/21/2013Francesco MicheliMajor ShareholderSell124,912$62.50$7,807,000.00View SEC Filing  
10/21/2013Jonathan SilversteinDirectorSell40,088$62.50$2,505,500.00View SEC Filing  
10/21/2013Luciano AdoriniInsiderSell2,000$55.51$111,020.00View SEC Filing  
10/15/2013Francesco MicheliMajor ShareholderSell1,123,415$62.50$70,213,437.50View SEC Filing  
10/15/2013Orbimed Advisors LlcDirectorSell376,585$62.50$23,536,562.50View SEC Filing  
10/2/2013David ShapiroCMOSell4,392$72.80$319,737.60View SEC Filing  
9/20/2013Luciano AdoriniInsiderSell2,000$61.07$122,140.00View SEC Filing  
9/17/2013Mark PruzanskiCEOSell25,000$52.00$1,300,000.00View SEC Filing  
9/13/2013Mark PruzanskiCEOSell12,500$49.02$612,750.00View SEC Filing  
8/20/2013Luciano AdoriniInsiderSell2,000$44.18$88,360.00View SEC Filing  
8/16/2013David ShapiroCMOSell5,016$49.20$246,787.20View SEC Filing  
8/15/2013David ShapiroCMOSell4,754$45.04$214,120.16View SEC Filing  
8/12/2013Mark PruzanskiCEOSell12,500$45.98$574,750.00View SEC Filing  
8/12/2013Paolo FundaroDirectorSell4,759$46.13$219,532.67View SEC Filing  
7/22/2013Luciano AdoriniInsiderSell2,000$49.44$98,880.00View SEC Filing  
7/15/2013Mark PruzanskiCEOSell25,000$50.05$1,251,250.00View SEC Filing  
7/9/2013Mark PruzanskiCEOSell37,500$46.36$1,738,500.00View SEC Filing  
7/8/2013Barbara Gayle DuncanCFOSell25,000$45.39$1,134,750.00View SEC Filing  
7/2/2013David ShapiroCMOSell4,369$43.63$190,619.47View SEC Filing  
6/26/2013Mark PruzanskiCEOSell12,500$40.06$500,750.00View SEC Filing  
6/20/2013Luciano AdoriniInsiderSell2,000$37.07$74,140.00View SEC Filing  
6/20/2013Mark PruzanskiCEOSell25,000$38.25$956,250.00View SEC Filing  
6/19/2013Barbara Gayle DuncanCFOSell50,575$34.50$1,744,837.50View SEC Filing  
6/17/2013David ShapiroCMOSell5,016$32.72$164,123.52View SEC Filing  
5/28/2013Barbara Gayle DuncanCFOSell6,225$34.50$214,762.50View SEC Filing  
5/20/2013Barbara Gayle DuncanCFOSell28,200$34.50$972,900.00View SEC Filing  
5/16/2013David ShapiroCMOSell5,016$31.31$157,050.96View SEC Filing  
4/9/2013David ShapiroCMOSell3,750$34.41$129,037.50View SEC Filing  
10/16/2012Jonathan SilversteinDirectorBuy333,334$15.00$5,000,010.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Intercept Pharmaceuticals (NASDAQ ICPT) News Headlines

Source:
DateHeadline
Intercept Pharmaceuticals, Inc. – Value Analysis (NASDAQ:ICPT) : December 15, 2017Intercept Pharmaceuticals, Inc. – Value Analysis (NASDAQ:ICPT) : December 15, 2017
finance.yahoo.com - December 15 at 3:16 PM
Intercept Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ICPT-US : December 14, 2017Intercept Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ICPT-US : December 14, 2017
finance.yahoo.com - December 14 at 3:16 PM
Longs quietly moving into Intercept Pharma; shares up 9% - Seeking AlphaLongs quietly moving into Intercept Pharma; shares up 9% - Seeking Alpha
seekingalpha.com - December 14 at 5:32 AM
Want To Invest In Intercept Pharmaceuticals Inc (undefined:ICPT)? Here’s How It Performed LatelyWant To Invest In Intercept Pharmaceuticals Inc (undefined:ICPT)? Here’s How It Performed Lately
finance.yahoo.com - December 13 at 3:16 PM
Intercept: The Best of the Biotechs?Intercept: The Best of the Biotechs?
finance.yahoo.com - December 13 at 3:16 PM
Intercept Pharmaceuticals (ICPT) Now Covered by Deutsche BankIntercept Pharmaceuticals (ICPT) Now Covered by Deutsche Bank
www.americanbankingnews.com - December 12 at 10:06 PM
$44.33 Million in Sales Expected for Intercept Pharmaceuticals, Inc. (ICPT) This Quarter$44.33 Million in Sales Expected for Intercept Pharmaceuticals, Inc. (ICPT) This Quarter
www.americanbankingnews.com - December 12 at 6:30 AM
-$3.40 Earnings Per Share Expected for Intercept Pharmaceuticals, Inc. (ICPT) This Quarter-$3.40 Earnings Per Share Expected for Intercept Pharmaceuticals, Inc. (ICPT) This Quarter
www.americanbankingnews.com - December 10 at 7:22 PM
Intercept Pharmaceuticals (ICPT) Lowered to Sell at BidaskClubIntercept Pharmaceuticals (ICPT) Lowered to Sell at BidaskClub
www.americanbankingnews.com - December 9 at 5:46 PM
NASH Stocks Brace For Shockwaves From Galectin Therapeutics Trial Results - Seeking AlphaNASH Stocks Brace For Shockwaves From Galectin Therapeutics Trial Results - Seeking Alpha
seekingalpha.com - December 4 at 3:09 PM
Intercept Pharmaceuticals (ICPT) Upgraded to Sell at ValuEngineIntercept Pharmaceuticals (ICPT) Upgraded to Sell at ValuEngine
www.americanbankingnews.com - December 3 at 10:46 AM
Intercept Pharmaceuticals, Inc. Forecasted to Earn FY2017 Earnings of ($13.14) Per Share (ICPT)Intercept Pharmaceuticals, Inc. Forecasted to Earn FY2017 Earnings of ($13.14) Per Share (ICPT)
www.americanbankingnews.com - November 30 at 6:56 AM
Intercept Pharmaceuticals Appoints Christian Weyer as Executive Vice President of Research & Development - GlobeNewswire (press release)Intercept Pharmaceuticals Appoints Christian Weyer as Executive Vice President of Research & Development - GlobeNewswire (press release)
globenewswire.com - November 28 at 3:07 PM
Leerink Swann Reaffirms "Hold" Rating for Intercept Pharmaceuticals (ICPT)Leerink Swann Reaffirms "Hold" Rating for Intercept Pharmaceuticals (ICPT)
www.americanbankingnews.com - November 28 at 2:58 PM
Todays Research Reports on Trending Tickers: Aeterna Zentaris and Intercept PharmaceuticalsToday's Research Reports on Trending Tickers: Aeterna Zentaris and Intercept Pharmaceuticals
finance.yahoo.com - November 28 at 9:31 AM
Intercept Pharmaceuticals Appoints Christian Weyer as Executive Vice President of Research & DevelopmentIntercept Pharmaceuticals Appoints Christian Weyer as Executive Vice President of Research & Development
finance.yahoo.com - November 27 at 5:25 PM
FINAL DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Intercept Pharmaceuticals, Inc. and Lead Plaintiff Deadline: November 27, 2017FINAL DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Intercept Pharmaceuticals, Inc. and Lead Plaintiff Deadline: November 27, 2017
finance.yahoo.com - November 27 at 5:25 PM
Intercept Pharmaceuticals, Inc. (ICPT) Receives Average Rating of "Hold" from AnalystsIntercept Pharmaceuticals, Inc. (ICPT) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - November 26 at 7:46 AM
DEADLINE ALERT: Brower Piven Reminds Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT) To Contact The FirmDEADLINE ALERT: Brower Piven Reminds Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT) To Contact The Firm
finance.yahoo.com - November 23 at 2:01 AM
ICPT SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of Commencement of a Class Action Involving Intercept Pharmaceuticals, Inc. and a Lead Plaintiff Deadline of November 27, 2017ICPT SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of Commencement of a Class Action Involving Intercept Pharmaceuticals, Inc. and a Lead Plaintiff Deadline of November 27, 2017
finance.yahoo.com - November 23 at 2:01 AM
Zacks: Analysts Anticipate Intercept Pharmaceuticals, Inc. (ICPT) to Post -$3.39 EPSZacks: Analysts Anticipate Intercept Pharmaceuticals, Inc. (ICPT) to Post -$3.39 EPS
www.americanbankingnews.com - November 22 at 7:08 PM
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Intercept Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of November 27, 2017 - ICPTSHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Intercept Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of November 27, 2017 - ICPT
finance.yahoo.com - November 22 at 12:56 AM
DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Intercept Pharmaceuticals, Inc. and Lead Plaintiff Deadline: November 27, 2017DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Intercept Pharmaceuticals, Inc. and Lead Plaintiff Deadline: November 27, 2017
finance.yahoo.com - November 20 at 8:09 PM
Intercept Pharmaceuticals, Inc. (ICPT) Receives "Buy" Rating from WedbushIntercept Pharmaceuticals, Inc. (ICPT) Receives "Buy" Rating from Wedbush
www.americanbankingnews.com - November 20 at 7:40 AM
ICPT EQUITY ALERT: The Law Offices of Vincent Wong Reminds Investors of Commencement of a Class Action Involving Intercept Pharmaceuticals, Inc. and a Lead Plaintiff Deadline of November 27, 2017ICPT EQUITY ALERT: The Law Offices of Vincent Wong Reminds Investors of Commencement of a Class Action Involving Intercept Pharmaceuticals, Inc. and a Lead Plaintiff Deadline of November 27, 2017
finance.yahoo.com - November 17 at 11:38 PM
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Intercept Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of November 27, 2017 - ICPTINVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Intercept Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of November 27, 2017 - ICPT
finance.yahoo.com - November 17 at 6:37 PM
EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Intercept Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of November 27, 2017 – ICPTEQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Intercept Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of November 27, 2017 – ICPT
finance.yahoo.com - November 14 at 8:16 PM
3 Top Healthcare Stocks to Buy in November3 Top Healthcare Stocks to Buy in November
finance.yahoo.com - November 13 at 7:47 PM
SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Intercept Pharmaceuticals, Inc. and Lead Plaintiff Deadline: November 27, 2017SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Intercept Pharmaceuticals, Inc. and Lead Plaintiff Deadline: November 27, 2017
finance.yahoo.com - November 13 at 7:47 PM
November 27, 2017 LEAD PLAINTIFF DEADLINE ALERT: Monteverde & Associates PC Encourages Investors Who Suffered Significant Losses in Intercept Pharmaceuticals, Inc. To Contact The Firm - ICPTNovember 27, 2017 LEAD PLAINTIFF DEADLINE ALERT: Monteverde & Associates PC Encourages Investors Who Suffered Significant Losses in Intercept Pharmaceuticals, Inc. To Contact The Firm - ICPT
finance.yahoo.com - November 12 at 10:37 AM
The Klein Law Firm Reminds Shareholders of a Class Action Filed on Behalf of Intercept Pharmaceuticals, Inc. Shareholders and a Lead Plaintiff Deadline of November 27, 2017The Klein Law Firm Reminds Shareholders of a Class Action Filed on Behalf of Intercept Pharmaceuticals, Inc. Shareholders and a Lead Plaintiff Deadline of November 27, 2017
finance.yahoo.com - November 11 at 11:11 AM
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Intercept Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline – ICPTSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Intercept Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline – ICPT
finance.yahoo.com - November 11 at 11:11 AM
Intercept Pharmaceuticals, Inc. (ICPT) Forecasted to Post FY2017 Earnings of ($13.30) Per ShareIntercept Pharmaceuticals, Inc. (ICPT) Forecasted to Post FY2017 Earnings of ($13.30) Per Share
www.americanbankingnews.com - November 8 at 11:24 AM
EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Intercept Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of November 27, 2017 - ICPTEQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Intercept Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of November 27, 2017 - ICPT
finance.yahoo.com - November 8 at 10:10 AM
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Intercept Pharmaceuticals, Inc. – ICPTEQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Intercept Pharmaceuticals, Inc. – ICPT
feeds.benzinga.com - November 7 at 3:01 PM
SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Intercept Pharmaceuticals, Inc. & Lead Plaintiff Deadline: November 27, 2017SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Intercept Pharmaceuticals, Inc. & Lead Plaintiff Deadline: November 27, 2017
finance.yahoo.com - November 7 at 2:52 AM
ETFs with exposure to Intercept Pharmaceuticals, Inc. : November 6, 2017ETFs with exposure to Intercept Pharmaceuticals, Inc. : November 6, 2017
finance.yahoo.com - November 7 at 2:52 AM
ICPT EQUITY ALERT: The Law Offices of Vincent Wong Notifies Investors of Commencement of a Class Action Involving Intercept Pharmaceuticals, Inc. and a Lead Plaintiff Deadline of November 27, 2017ICPT EQUITY ALERT: The Law Offices of Vincent Wong Notifies Investors of Commencement of a Class Action Involving Intercept Pharmaceuticals, Inc. and a Lead Plaintiff Deadline of November 27, 2017
finance.yahoo.com - November 7 at 2:52 AM
Jefferies Group Weighs in on Intercept Pharmaceuticals, Inc.s FY2017 Earnings (ICPT)Jefferies Group Weighs in on Intercept Pharmaceuticals, Inc.'s FY2017 Earnings (ICPT)
www.americanbankingnews.com - November 6 at 4:56 AM
Intercept Pharmaceuticals, Inc. to Post FY2017 Earnings of ($12.07) Per Share, Seaport Global Securities Forecasts (ICPT)Intercept Pharmaceuticals, Inc. to Post FY2017 Earnings of ($12.07) Per Share, Seaport Global Securities Forecasts (ICPT)
www.americanbankingnews.com - November 6 at 4:56 AM
FY2017 EPS Estimates for Intercept Pharmaceuticals, Inc. (ICPT) Lifted by AnalystFY2017 EPS Estimates for Intercept Pharmaceuticals, Inc. (ICPT) Lifted by Analyst
www.americanbankingnews.com - November 6 at 4:56 AM
FY2017 EPS Estimates for Intercept Pharmaceuticals, Inc. (ICPT) Raised by AnalystFY2017 EPS Estimates for Intercept Pharmaceuticals, Inc. (ICPT) Raised by Analyst
www.americanbankingnews.com - November 6 at 4:56 AM
Intercept Pharmaceuticals, Inc. (ICPT) Expected to Post Quarterly Sales of $42.10 MillionIntercept Pharmaceuticals, Inc. (ICPT) Expected to Post Quarterly Sales of $42.10 Million
www.americanbankingnews.com - November 5 at 8:46 AM
Intercept (ICPT) Q3 Loss Narrower Than Expected, Sales BeatIntercept (ICPT) Q3 Loss Narrower Than Expected, Sales Beat
finance.yahoo.com - November 4 at 1:48 AM
Intercept Pharmaceuticals, Inc. (ICPT) Expected to Post Earnings of -$3.47 Per ShareIntercept Pharmaceuticals, Inc. (ICPT) Expected to Post Earnings of -$3.47 Per Share
www.americanbankingnews.com - November 3 at 5:06 PM
Intercept (ICPT) Q3 Loss Narrower Than Expected, Sales Beat - NasdaqIntercept (ICPT) Q3 Loss Narrower Than Expected, Sales Beat - Nasdaq
www.nasdaq.com - November 3 at 8:52 AM
Intercept Pharmaceuticals (ICPT) Q3 2017 Results - Earnings Call Transcript - Seeking AlphaIntercept Pharmaceuticals (ICPT) Q3 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - November 3 at 8:52 AM
Equities Analysts Offer Predictions for Intercept Pharmaceuticals, Inc.s Q1 2018 Earnings (ICPT)Equities Analysts Offer Predictions for Intercept Pharmaceuticals, Inc.'s Q1 2018 Earnings (ICPT)
www.americanbankingnews.com - November 2 at 1:02 PM
Noteworthy Wednesday Option Activity: GPRO, MAR, ICPT - Nasdaq ... - NasdaqNoteworthy Wednesday Option Activity: GPRO, MAR, ICPT - Nasdaq ... - Nasdaq
www.nasdaq.com - November 2 at 1:46 AM
Bragar Eagel & Squire, PC Announces That a Class Action Lawsuit Has Been Filed Against Intercept Pharmaceuticals ... - Business Wire (press release)Bragar Eagel & Squire, PC Announces That a Class Action Lawsuit Has Been Filed Against Intercept Pharmaceuticals ... - Business Wire (press release)
www.businesswire.com - November 2 at 1:46 AM

SEC Filings

Intercept Pharmaceuticals (NASDAQ:ICPT) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Intercept Pharmaceuticals (NASDAQ:ICPT) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Intercept Pharmaceuticals (NASDAQ ICPT) Stock Chart for Saturday, December, 16, 2017

Loading chart…

This page was last updated on 12/16/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.